Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOVERT conversion therapy in colorectal cancer with peritoneal metastases
2026-526122-41-00Phase 2Authorised
- Sponsor
- Akademiska sjukhuset
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin, paclitaxel, docetaxel, gemcitabine, oxaliplatin and 3 more in colorectal cancer (CRC) (4 arms), sponsored by Akademiska sjukhuset. Primary endpoint: Objective response rate by radiological PCI after 3 cycles. Planned start Jul 2026; status: authorised.
02
Drugs
cisplatinpaclitaxeldocetaxelgemcitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2026-526122-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526122-41-00.